T cell stimulating therapy include the checkpoint inhibitors or agonist antibodies to improve T cell activity, the utilization of bsAbs to redirect T cells to tumor cells, autologous T cell ex vivo activation combined with bispecific antibodies, CAR T cells with engineered antibodies replacing TCRs, and T cells expressing CD16a with anti-tumor antibodies (e.g., Anti-CD20, or anti-BCMA). This evidence concerns the gene TNFRSF17 and neoplasm.